Adagene Inc - ADR
ADAG
Get informed when a big investor buys or sells
+ FollowMarket Cap$149.46M
Close$
$1.68
52.5% downside
Current Fair Value
52.5% downsideOvervalued by 52.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $149.46 Million |
|---|---|
| Enterprise Value | $85.67 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.46 |
| Beta | 0.57 |
| Outstanding Shares | 37,908,475 |
Return
| Return on Equity | -168.56% |
|---|---|
| Return on Assets | -76.13% |
| Return on Invested Capital | -114.35% |
Valuation & Multiples
| P/E Ratio | -8.52 |
|---|---|
| PEG | 10.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 10.99 |
| Enterprise Value to EBIT | -1.41 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 1, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$17.50 M
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$17.50 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.74%▲ 0.54% |
|---|---|
| Total Invested | $9.70M▲ 60.93% |
| Investors Holding | 25▲ 8.00% |
ESG Score
No data
About Adagene Inc
2,020 employeesAdagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial int...